Logo

American Heart Association

  2
  0


Final ID: MDP1085

Resting Heart Rate Trajectories over 25 Years: Patterns, Predictors, and Prognostic Impact in the Atherosclerosis Risk in Communities (ARIC) Study

Abstract Body (Do not enter title and authors here): Background: Abnormal resting heart rate (RHR) is associated with cardiovascular events and mortality. Longitudinal RHR trajectories may offer unique prognostic, but research exploring these trajectories over extended periods and their prognostic implications is limited.
Methods: Using data from 5,794 participants in the Atherosclerosis Risk in Communities (ARIC) study, we first characterized RHR trajectories over 25 years (from visit 1 [1987-89] to visit 5 [2011-13]) with latent class growth mixture models. Then, we determined the predictors of those trajectories using multinomial logistic regression (n=5,432 with data on predictors of interest). We ran Cox models to quantify the associations between RHR trajectories with cardiovascular outcomes (coronary heart disease, heart failure, stroke) and all-cause mortality (n=4,329 free of cardiovascular disease at baseline).
Results: We identified one typical pattern (stable/slight decline, 88.4%) and three atypical patterns (stable-slight increase, 9.2%; increase-decrease, 2.0%; stable-sharp increase, 0.4%) (Figure-Left panel). Obesity, ever smoking, a history of heart failure, and lower education levels predicted the atypical patterns. The stable-increase (combined for slight and sharp) trajectory was significantly and robustly associated with heart failure and all-cause mortality (Figure-Right panel). The increase-decrease trajectory showed a hazard ratio of ~2 for coronary heart disease, although statistical significance was restricted in the demographically adjusted model.
Conclusions: We identified one typical (stable/slight decline) and three atypical (increase-decrease, stable-slight increase, and stable-sharp increase) RHR trajectories over 25 years. The atypical trajectories, particularly the stable-increase pattern, were associated with poorer prognosis. These findings highlight the value of monitoring long-term RHR trajectories for cardiovascular risk assessment.
  • Meng, Ning  ( Johns Hopkins Unversity , Baltimore , Maryland , United States )
  • Mok, Yejin  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Soliman, Elsayed  ( WAKE FOREST SCHOOL OF MEDICINE , Winston Salem , North Carolina , United States )
  • Chen, Lin  ( UNIVERSITY OF MINNESOTA , Minneapolis , Minnesota , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Solomon, Scott  ( BRIGHAM AND WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Matsushita, Kuni  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Author Disclosures:
    Ning Meng: DO NOT have relevant financial relationships | Yejin Mok: DO NOT have relevant financial relationships | Elsayed Soliman: DO NOT have relevant financial relationships | Lin Chen: DO NOT have relevant financial relationships | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now) | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now) | Kuni Matsushita: DO have relevant financial relationships ; Consultant:RhythmX AI:Active (exists now) ; Research Funding (PI or named investigator):Resolve to Save Lives:Active (exists now) ; Other (please indicate in the box next to the company name):Fukuda Denshi:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Preventive Strategies for Cardiovascular Disease from Childhood to Adulthood

Sunday, 11/17/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
Adherence to Lipid Lowering Therapy among US Veterans with Atherosclerotic Cardiovascular Disease

Ward Rachel, Gaziano Michael, Wellman Helen, Yel Nedim, Young Melissa, Coleman-lopez Mason, Niu Xiaoli, Mcelligott Sean, Gagnon David, Djousse Luc

Longitudinal Assessment Using a Mobile Text-Messaging Based Platform Demonstrates High Rates of Transitions in Dual Users of Electronic and Combustible Cigarettes

Burns Madeleine, Minetti Erika, Palmisano Joseph, Hoover Rachel, Bhatnagar Aruni, Robertson Rose, Keith Rachel, Hamburg Naomi

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available